POZEN Inc

POZEN — Merger or Acquisition (September 2015)

11 slides from POZEN's merger presentation, Sep 28, 2015

  1. Slide 1: Strategic Rationale and Vision for Aralez Pharmaceuticals

    “Strategic Rationale and Vision for Aralez Pharmaceuticals” September 2015

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equit

  3. Slide 3: A Transformational Combination

    A Transformational Combination Strong Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Irish Domicile Offers Financial & Competitive Advantage $150M at close ($75m equity/$75m convertible note) $200M committed cr

  4. Slide 4: POZEN is a US specialty pharmaceutical company

    POZEN is a US specialty pharmaceutical company that has developed multiple novel combination therapies for pain and cardiovascular diseases YOSPRALA™: Combination of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke Awaiting FDA approval

  5. Slide 5: YOSPRALA: Significant Commercial Opportunity

    YOSPRALA: Significant Commercial Opportunity YOSPRALA is a unique formulation of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke Market Opportunity ~24 MM* secondary prevention patients in US 70% take aspirin** Over 40% of physicians p

  6. Slide 6: YOSPRALA Update

    YOSPRALA API Aspirin Manufacturer Status YOSPRALA API primary aspirin manufacturer executing against its action plan to address FDA issues: will be subject to FDA re-inspection Steps also being taken to qualify a second supplier of aspirin API Prelaunch Preparations Scaling up and building out comme

  7. Slide 7: Tribute: Compelling Canadian Growth Story

    Tribute: Compelling Canadian Growth Story Tribute is a Canadian specialty pharmaceutical company Sales force of 28 sales representatives across Canada 20 primary care targeting PCPs/GPs, neurologists & dermatologists 8 specialty care targeting pain, GI specialists and others Acquired Medical Futures

  8. Slide 8: Aralez – Strong Projected Revenue Growth

    Aralez – Strong Projected Revenue Growth* $75M equity Robust balance sheet and demonstrated access to capital $75M convertible debt 2.5% with 32.5% premium $200M credit facility For future acquisitions * Figures reflect the addition of standalone projections and do not include any synergies or chang

  9. Slide 9: The Aralez Growth Strategy & Priorities

    The Aralez Growth Strategy & Priorities Maximize the value of expanded portfolio & geographic footprint Build around a cardiovascular-based, North American-focused portfolio Aggressive approach to CD&L and M&A to drive growth supported by new platform Leverage platform for growth with tax-efficient

  10. Slide 10: Our Near Term Priorities

    Advance YOSPRALA to submission and approval Focus on YOSPRALA prelaunch preparations & execute commercialization strategy Successfully close the Tribute Pharmaceuticals merger in the 4Q15 S4 remains subject to SEC review; In the process of responding to the SEC’s comments Finalize S-4 and go effecti

  11. Slide 11: Strategic Rationale and Vision for Aralez Pharmaceuticals

    “Strategic Rationale and Vision for Aralez Pharmaceuticals” September 2015

Pozen — Merger or Acquisition (September 2015) on 6ix